TP53 and cancer: Importantly, the above-listed Class I and pan-HDAC inhibitors have been reported as successful anticancer agents as they induce cell-cycle arrest, differentiation and/or apoptosis in cancer cells by increasing the acetylation status of the chromatin and various non-histone proteins, such as p53, leading to their stabilization and activation.